Autres langues Telix Pharmaceuticals Limited

Actions

TLX

AU000000TLX2

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:13:48 11/09/2026			Varia. 5j.	Varia. 1 janv.
15,67 ^AUD	-6,50%		-4,86%	+39,91%

05:54	Les plus fortes baisses de l'ASX	MT
03/09	Les plus fortes hausses de l'ASX	MT

Autres langues

05:54	ASX Biggest Losers
09/09	Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
03/09	ASX Biggest Gainers
02/09	Telix Pharmaceuticals Completes Patient Enrollment for Phase 3 Study of Imaging Agents in Prostate Cancer
02/09	Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging
02/09	Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
02/09	Telix Pharmaceuticals Limited Completes Enrollment In Phase 3 BiPASS Study Of Illuccix And Gozellix For Prostate Cancer Imaging
01/09	Telix Pharmaceuticals Names David Gill as Chair
01/09	Telix Pharmaceuticals Limited Announces Chair of the Board Changes
01/09	Telix Pharmaceuticals Appoints Chair
01/09	Telix Appoints David Gill as Chair
20/08	Telix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
20/08	Telix Pharmaceuticals Logs Profit in H1; Revenue Up
20/08	Telix Pharmaceuticals : HY26 Results Announcement
07/08	ASX Biggest Gainers
05/08	Telix to Host R&D Day in New York City on September 22, 2026
24/07	Telix Says Thyroid Cancer Therapy Candidate Shows Encouraging Disease Control, Acceptable Safety Profile in Real-World Data Review
24/07	EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
22/07	Telix Pharmaceuticals Limited Publishes Results from Prostact Select Study Evaluating Tlx591-Tx Therapy Candidate
21/07	TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
21/07	Telix Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2026
21/07	Telix Pharmaceuticals Limited and Regeneron Pharmaceuticals, Inc. Enter into Strategic Collaboration to Jointly Develop and Commercialize Next-Generation Radiopharmaceutical Therapies and Advance Multiple Novel Oncology Programs
21/07	Telix Pharmaceuticals Limited Doses First Patient In Phase 3 LUTEON Trial Of TLX250-Tx For Renal Cancer
21/07	Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the Second Quarter Ended June 30, 2026